EAP for the Treatment of Glioblastoma With PVSRIPO
- Conditions
- Glioblastoma
- Registration Number
- NCT04599647
- Lead Sponsor
- Istari Oncology, Inc.
- Brief Summary
This is an open-label, single-arm, non-randomized, intermediate-sized expanded access study evaluating the safety, efficacy, and tolerability of PVSRIPO delivered via intratumoral infusion, in subjects with glioblastoma (GBM) who are ineligible to participate in clinical study with PVSRIPO that is currently open to enrollment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which PVSRIPO exerts oncolytic activity in glioblastoma?
How does PVSRIPO treatment compare to standard-of-care therapies for recurrent glioblastoma in clinical outcomes?
Which biomarkers correlate with improved survival following PVSRIPO intratumoral infusion in GBM patients?
What are the most common adverse events associated with PVSRIPO therapy in expanded access glioblastoma protocols?
Are there any combination therapies being explored with PVSRIPO to enhance glioblastoma treatment efficacy?
Trial Locations
- Locations (1)
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
Duke University Medical Center🇺🇸Durham, North Carolina, United States